NASDAQ:ATRS

Antares Pharma Competitors

$4.07
-0.03 (-0.73 %)
(As of 04/12/2021 04:46 PM ET)
Add
Compare
Today's Range
$4.03
Now: $4.07
$4.10
50-Day Range
$3.97
MA: $4.28
$4.85
52-Week Range
$2.39
Now: $4.07
$5.07
Volume485,534 shs
Average Volume1.30 million shs
Market Capitalization$684.42 million
P/E Ratio67.84
Dividend YieldN/A
Beta1.44

Competitors

Antares Pharma (NASDAQ:ATRS) Vs. ALGN, WST, COO, XRAY, HAE, and QDEL

Should you be buying ATRS stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Antares Pharma, including Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), and Quidel (QDEL).

Antares Pharma (NASDAQ:ATRS) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of current recommendations for Antares Pharma and Align Technology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Antares Pharma00403.00
Align Technology13902.62

Antares Pharma currently has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Align Technology has a consensus target price of $501.3333, indicating a potential downside of 16.65%. Given Antares Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Antares Pharma is more favorable than Align Technology.

Valuation & Earnings

This table compares Antares Pharma and Align Technology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Antares Pharma$123.86 million5.53$-2,030,000.00($0.01)-407.00
Align Technology$2.41 billion19.76$442.78 million$4.96121.19

Align Technology has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Antares Pharma and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Antares Pharma6.64%16.48%6.69%
Align Technology76.00%68.99%46.64%

Institutional and Insider Ownership

39.9% of Antares Pharma shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 5.9% of Antares Pharma shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Summary

Align Technology beats Antares Pharma on 10 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for West Pharmaceutical Services and Antares Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
Antares Pharma00403.00

West Pharmaceutical Services presently has a consensus target price of $310.00, indicating a potential upside of 4.48%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Antares Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Antares Pharma is more favorable than West Pharmaceutical Services.

Earnings and Valuation

This table compares West Pharmaceutical Services and Antares Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion11.92$241.70 million$3.2491.65
Antares Pharma$123.86 million5.53$-2,030,000.00($0.01)-407.00

West Pharmaceutical Services has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares West Pharmaceutical Services and Antares Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
Antares Pharma6.64%16.48%6.69%

Institutional & Insider Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

West Pharmaceutical Services beats Antares Pharma on 9 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for The Cooper Companies and Antares Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Cooper Companies04602.60
Antares Pharma00403.00

The Cooper Companies presently has a consensus target price of $384.25, indicating a potential downside of 0.95%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Antares Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Antares Pharma is more favorable than The Cooper Companies.

Earnings and Valuation

This table compares The Cooper Companies and Antares Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cooper Companies$2.43 billion7.85$238.40 million$9.6440.25
Antares Pharma$123.86 million5.53$-2,030,000.00($0.01)-407.00

The Cooper Companies has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares The Cooper Companies and Antares Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The Cooper Companies9.81%12.79%7.20%
Antares Pharma6.64%16.48%6.69%

Institutional & Insider Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

The Cooper Companies has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

The Cooper Companies beats Antares Pharma on 9 of the 14 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for DENTSPLY SIRONA and Antares Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DENTSPLY SIRONA15702.46
Antares Pharma00403.00

DENTSPLY SIRONA presently has a consensus target price of $55.3333, indicating a potential downside of 13.76%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Antares Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Antares Pharma is more favorable than DENTSPLY SIRONA.

Earnings and Valuation

This table compares DENTSPLY SIRONA and Antares Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$4.03 billion3.49$262.90 million$2.4526.18
Antares Pharma$123.86 million5.53$-2,030,000.00($0.01)-407.00

DENTSPLY SIRONA has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DENTSPLY SIRONA and Antares Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DENTSPLY SIRONA-1.40%7.13%4.13%
Antares Pharma6.64%16.48%6.69%

Institutional & Insider Ownership

96.0% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

DENTSPLY SIRONA has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

Antares Pharma beats DENTSPLY SIRONA on 9 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Haemonetics and Antares Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics00403.00
Antares Pharma00403.00

Haemonetics presently has a consensus target price of $144.80, indicating a potential upside of 24.21%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Antares Pharma's higher possible upside, analysts plainly believe Antares Pharma is more favorable than Haemonetics.

Earnings and Valuation

This table compares Haemonetics and Antares Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million5.99$76.53 million$3.3135.22
Antares Pharma$123.86 million5.53$-2,030,000.00($0.01)-407.00

Haemonetics has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Haemonetics and Antares Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics11.76%22.85%10.40%
Antares Pharma6.64%16.48%6.69%

Institutional & Insider Ownership

96.2% of Haemonetics shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 1.6% of Haemonetics shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

Haemonetics beats Antares Pharma on 8 of the 12 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and Antares Pharma (NASDAQ:ATRS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Quidel and Antares Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel10302.50
Antares Pharma00403.00

Quidel presently has a consensus target price of $262.75, indicating a potential upside of 106.24%. Antares Pharma has a consensus target price of $5.6250, indicating a potential upside of 38.21%. Given Quidel's higher possible upside, equities research analysts plainly believe Quidel is more favorable than Antares Pharma.

Profitability

This table compares Quidel and Antares Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel36.91%63.31%40.55%
Antares Pharma6.64%16.48%6.69%

Earnings and Valuation

This table compares Quidel and Antares Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million10.07$72.92 million$2.7346.63
Antares Pharma$123.86 million5.53$-2,030,000.00($0.01)-407.00

Quidel has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

84.0% of Quidel shares are held by institutional investors. Comparatively, 39.9% of Antares Pharma shares are held by institutional investors. 14.1% of Quidel shares are held by company insiders. Comparatively, 5.9% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Quidel has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

Quidel beats Antares Pharma on 10 of the 14 factors compared between the two stocks.


Antares Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$601.11-1.4%$46.89 billion$2.41 billion27.35
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$296.94-0.1%$21.90 billion$1.84 billion78.35
The Cooper Companies logo
COO
The Cooper Companies
1.9$388.02-0.5%$18.97 billion$2.43 billion80.67
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$64.15-0.1%$14.06 billion$4.03 billion-278.91
Haemonetics logo
HAE
Haemonetics
1.6$116.58-0.4%$5.95 billion$988.48 million56.32
Quidel logo
QDEL
Quidel
2.4$127.30-3.2%$5.39 billion$534.89 million14.94
STAAR Surgical logo
STAA
STAAR Surgical
1.4$114.08-1.6%$5.31 billion$150.18 million600.45
Neogen logo
NEOG
Neogen
1.2$91.26-1.4%$4.95 billion$418.17 million80.05
ICU Medical logo
ICUI
ICU Medical
1.5$205.50-0.6%$4.33 billion$1.27 billion54.37
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$60.69-1.3%$3.42 billion$994.85 million-114.51News Coverage
Atrion logo
ATRI
Atrion
1.1$645.10-0.2%$1.18 billion$155.07 million36.34News Coverage
Meridian Bioscience logo
VIVO
Meridian Bioscience
1.7$24.02-4.2%$1.08 billion$253.67 million22.24
Cerus logo
CERS
Cerus
1.7$6.07-1.0%$1.03 billion$74.65 million-15.56Analyst Revision
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.05-3.7%$749.68 million$154.60 million-43.70
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.40-1.5%$570.33 million$114.51 million-85.96
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.49-0.1%$319.17 million$46.90 million27.60News Coverage
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.